Cyclo Therapeutics' Trappsol Phase 1/2 Trial In Niemann-Pick Type C1 Patients Meets Endpoints

(RTTNews) - Cyclo Therapeutics, Inc. (CYTH) Thursday announced that its phase 1/2clinical trial using intravenous trappsol in Niemann-Pick Type C1 patients met primary endpoints. The double blind study was done in patients aged 2 to 39 years in clinical sites in the U.K., Israel Sweden.

The company said the positive data might help advance its upcoming Phase 3 clinical trial in the coming quarter.

1500 mg/kg, 2000 mg/kg, and 2500 mg/kg and dose groups showed a favorable safety profile, consistent with previously reported data from a companion Phase 1 clinical trial.

Out of 9 patients, who completed the study, 8 met the first efficacy endpoint.

The clinical stage biotechnology company noted that the genetic disease Niemann Pick C1 causes cholesterol accumulation in cells, leading to dysfunction of liver, lung, spleen and brain and premature death.